New nasal COVID vaccine could replace shots

NCT ID NCT07215520

Ongoing ⭐️ VACCINE ⭐️ Sponsor: CastleVax Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This Phase 2a trial tests a new nasal COVID-19 vaccine (NDV-HXP-S-KP.2) against an approved mRNA shot in 200 adults who have already been vaccinated. The goal is to see if the nasal vaccine is safe and tolerable. Participants are either 65 or older, or 18-64 with a condition that raises their risk for severe COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Newcastle disease virus-based nasal COVID-19 vaccine (NDV-HXP-S-KP.2)
What this could lead to: If successful, this could provide a needle-free, mucosal COVID-19 booster option that may reduce transmission and offer longer-lasting protection.
What could go wrong: This is an early Phase 2a trial with only 200 participants, so results may not generalize. The vaccine uses a novel virus-based platform, and safety or immune response may not match the approved mRNA vaccines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Skylight Health Research

Colorado Springs, Colorado, 80917, United States
Skylight Health Research

Burlington, Massachusetts, 01803, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.